The collaboration is meticulously designed to fill a critical gap in the research ecosystem, where promising scientists often diverge toward adult cancer studies or pharmaceutical sectors due to the scarcity of dedicated pediatric-oriented funding. As James R. Downing, MD, President and CEO of St. Jude, articulates, this program aims not only to propel scientific discovery but to cultivate the next generation of leaders who will actively redefine therapeutic approaches for children facing the most aggressive and resistant cancer types. The focus extends beyond immediate cure rates to addressing long-term toxicity and side effects that can dramatically impair survivors’ quality of life.

The newly appointed fellows are spearheading innovative projects with profound technical intricacies. Dr. Keene Abbott, utilizing his expertise in molecular biology from MIT and his postdoctoral period at the Dana-Farber Cancer Institute, investigates a unique protein critical for DNA replication and repair in Ewing sarcoma cells. His hypothesis is that these cancer cells exhibit disproportionate reliance on this protein, rendering it a molecular vulnerability. By elucidating the biochemical pathways and structural biology underpinning this dependence, Abbott’s research could unlock less toxic, targeted therapeutics, moving away from conventional chemoradiation strategies that have stagnated for decades.

Meanwhile, Dr. Abigail Clevenger combines advanced single-cell profiling methodologies, including transcriptomics and proteomics, with patient-derived tumor samples to dissect cellular heterogeneity and immune evasion mechanisms in Ewing sarcoma. Her work, rooted in bioengineering principles from Rice University, focuses on understanding how intracellular cytoskeletal architectures facilitate tumor progression and immune suppression. By mapping these dynamic intracellular processes, Clevenger aims to inform combinatorial immunotherapeutic interventions that can disrupt these malignancies’ evasion tactics and enhance immune-mediated tumor eradication.

Dr. Amy Li’s investigation centers on mitigating chronic graft-versus-host disease (cGVHD), a severe immune complication following hematopoietic stem cell transplantation, a primary curative modality in pediatric acute leukemias. Her research leverages CRISPR-Cas9 genetic screens and in vivo murine models to analyze the modulatory impact of thalidomide analogs on regulatory T cells (Tregs). These immunosuppressive cells are pivotal in maintaining tolerance and reducing autoimmune reactions post-transplant. Li’s cutting-edge interrogation aims to delineate molecular pathways that can be pharmacologically targeted to enhance Treg survival and function, thereby reducing cGVHD morbidity and mortality.

In another novel exploration, Dr. Emily Phillips harnesses immunoengineering techniques to manipulate memory-like natural killer (NK) cells, which exhibit potent cytotoxicity against acute myeloid leukemia (AML), particularly chemo-resistant forms frequent in pediatric relapses. Her methodology includes genetic modification of NK cells with chimeric antigen receptors (CARs) or natural killer cell engagers (NKCEs) to boost specificity and killing efficiency against AML surface antigens. Phillips’ work at Washington University could propel these modified NK cells from bench to bedside, heralding an era of personalized immunotherapy designed to overcome chemo-refractory hematological cancers.

Addressing another formidable challenge, Dr. Cary Weiss’s research inspects translocation renal cell carcinoma (tRCC), a rare but particularly aggressive kidney cancer prevalent in young patients. By deploying advanced genomic and transcriptomic assays alongside functional genetics, Weiss seeks to decode the oncogenic dependencies driven by rare fusion proteins characteristic of tRCC. Due to the intrinsic difficulty in directly targeting fusion oncoproteins, Weiss’s approach focuses on identifying auxiliary pathways essential for tumor cell survival, thereby exposing novel druggable targets. His findings could have extensive applications across other fusion-driven pediatric cancers, potentially revolutionizing treatment paradigms.

The Damon Runyon-St. Jude Fellowship attempts not only to support these immersed scientific explorations but also to foster an integrated community of pediatric cancer researchers. Beyond financial backing, the program offers fellows debt relief, acknowledging the significant burden of medical school loans, an incentive designed to retain leading talent in the pediatric oncology niche. Moreover, the fellowship provides participants the unique opportunity to engage in annual symposia at the St. Jude Comprehensive Cancer Center, facilitating collaborative exchanges that may accelerate translational breakthroughs.

The urgency of dedicating tailored resources to pediatric oncology cannot be overstated. As Dr. Yung S. Lie of Damon Runyon emphasizes, without strategic funding aimed at the biological distinctiveness of pediatric cancers, researchers risk diluting their focus or abandoning the field, with dire consequences for treatment advancement. The stark differences in genetic mutations, tumor microenvironments, and etiological factors between adult and pediatric cancers necessitate distinct investigative frameworks and therapeutic innovations.

Despite the remarkable strides in adult cancer immunotherapies and precision medicine, pediatric cancer patients have historically lagged in benefiting from these advances, largely due to their illnesses’ unique pathological and molecular profiles. Dr. Philip T. Pauerstein, one of the 2024 fellows, poignantly captures this reality, underscoring the critical need for dedicated pediatric research programs like the Damon Runyon-St. Jude Fellowship that target the fundamental causative drivers of childhood cancers.

The broader implications of this partnership extend beyond immediate clinical outcomes; it represents a commitment to a long-term vision for children worldwide, aiming to drastically improve survival rates while minimizing the devastating physical and psychological impact of current treatments. As the fellows’ research progresses, it is anticipated that their insights will catalyze novel drug development, improved immune modulation therapies, and refined genetic and epigenetic targeting approaches — all tailored to the unique biology of pediatric cancers.

This fellowship program is a beacon of hope that suggests the pediatric oncology research landscape is poised for a renaissance, driven by interdisciplinary collaborations, state-of-the-art molecular techniques, and a compassionate commitment to the next generation of patients. By investing in the innovative minds that form this new class of fellows, the Damon Runyon Cancer Research Foundation and St. Jude Children’s Research Hospital are laying the groundwork for a future where childhood cancer is not merely survived but effectively cured with precision and grace.

Subject of Research: Pediatric cancer research, focusing on novel molecular targets, immunotherapies, and translational medicine approaches to improve diagnosis and treatment of pediatric malignancies.

Article Title: Innovating Pediatric Cancer Research: The Damon Runyon-St. Jude Fellowship Paves the Way for Breakthroughs

News Publication Date: 2024

Web References:
– https://www.damonrunyon.org/for-scientists/application-guidelines/st-jude-fellowship
– https://www.stjude.org/
– https://damonrunyon.org/

Keywords: Pediatric cancer, Ewing sarcoma, acute myeloid leukemia, translocation renal cell carcinoma, immunotherapy, regulatory T cells, natural killer cells, molecular targets, translational medicine, chronic graft-versus-host disease, DNA replication proteins, fusion oncoproteins, childhood cancer research

Among the six recipients of the Damon Runyon-Dale F. Frey Award, Dr. Fangtao Chi of MIT is delving into the nuanced interplay between dietary nutrients and cellular metabolism as they influence intestinal regeneration and tumorigenesis. His work focuses on how the intestine’s rapid self-renewal, mediated by intestinal stem cells, is affected by metabolic signals derived from diet. While these metabolic pathways promote tissue repair after damage such as inflammation or cancer therapy, Dr. Chi’s groundbreaking investigations also reveal that the same regenerative mechanisms can be subverted to fuel abnormal cellular growth, leading to tumors. By systematically dissecting these nutrient-metabolism pathways, Dr. Chi aims to establish dietary strategies that optimize tissue repair while mitigating colorectal and other intestinal cancers.

Dr. Cayla E. Jewett at the University of Colorado, Denver Anschutz Medical Campus is tackling an intriguing paradox presented by multiciliated cells. These specialized cells generate an abundance of centrioles—cellular organelles ordinarily tightly regulated to prevent cancerous transformation. Surprisingly, multiciliated cells manage to safely increase centriole numbers and use the DNA damage response pathway normally associated with oncogenic stress as part of their development. Dr. Jewett’s research seeks to decode how such cells reconcile these contradictory features, hoping to uncover novel molecular checkpoints that prevent tumorigenesis. Insights from this research may identify new therapeutic targets that inhibit abnormal centriole amplification in cancer cells while sparing normal tissue.

At Princeton University, Dr. Titas Sengupta investigates how epigenetic modifications of histones—proteins around which DNA is wrapped—influence gene regulation in neurons, especially regarding aging and environmental responses. Her work has unveiled mechanisms by which rapid histone modifications modulate neuronal functions such as short-term memory, highlighting that dynamic gene expression changes rather than static protein reserves underlie these cognitive processes. This line of inquiry is highly relevant to understanding the epigenetic dysregulation often observed in cancers affecting nervous tissues, providing a potential framework for uncovering how altered chromatin landscapes contribute to cancer progression and neurological dysfunction.

Dr. Dylan M. Parker of the University of Colorado, Boulder studies stress granules—membraneless molecular condensates that form within cells under stress conditions, impacting gene expression and cell survival. Stress granules are garnering attention for their roles in cancer, particularly in how their dynamics could promote tumor progression and resistance to chemotherapy. Dr. Parker aims to elucidate the molecular controls governing stress granule assembly and disassembly, advancing our understanding of how cancer cells adapt to treatment. Such knowledge might open avenues for developing drugs that disrupt granule formation, thereby sensitizing resistant tumors to existing therapies.

At the University of Pennsylvania, Dr. Catherine Triandafillou explores error correction mechanisms during early development using gastruloids, three-dimensional stem cell clusters that mimic embryonic patterning. Her microscopy-enabled lineage-tracing studies assess how deviations in cellular behavior impact developmental outcomes and the capacity of tissues to correct aberrations. Understanding how these processes fail in cancer could illuminate why tumors contain abnormal cellular compositions and proliferate unchecked. Dr. Triandafillou’s work aims to uncover cellular and tissue-level responses to early developmental errors, potentially revealing new approaches to target cancer’s root defects.

Dr. Youngmu (Nick) Shin from UCSF is pioneering the engineering of scaffold proteins to reconstruct and probe cell-cell communication interfaces known as synapses. By building synthetic synapses through designed protein condensates, he strives to elucidate the physical principles governing synaptic organization and strength. Insights from this synthetic biology approach have profound implications for immunotherapy, including engineering immune cells like T cells to form precise, robust connections with cancer cells, enhancing their ability to target malignancies while minimizing damage to healthy tissues.

The November 2025 cohort of Damon Runyon Fellows also exemplifies the breadth and depth of current cancer research. Dr. Duaa H. Al-Rawi at Memorial Sloan Kettering focuses on the earliest genetic disruptions in high-grade serous ovarian cancer, particularly alterations in the p53 tumor suppressor pathway and chromosomal instability in fallopian tube cells. By modeling these initial events, her research aims to inform early detection and prevention strategies for this deadly cancer subtype.

Dr. Tatsat Banerjee from the Whitehead Institute investigates the fundamental signaling architecture within CAR T cells—immune cells genetically reprogrammed for cancer therapy—seeking to enhance their ability to recognize and persist against solid tumors like melanoma. His innovative melding of molecular genetics and biophysics targets improvements in the immunological synapse’s function, essential for T cell-mediated tumor eradication.

Leukemia translation regulation is the focus for Dr. Elizabeth Black, also at the Whitehead Institute. Her research zeroes in on translation start site selection, a nuanced control point of protein synthesis that is dysregulated in blood cancers but overlooked due to experimental challenges. Understanding how cancer cells manipulate translation initiation could herald novel therapeutic interventions.

At UCSF, Dr. Sarah W. Cai investigates how TRP ion channel receptors, key mediators of pain, form nanoscale clusters in sensory neurons during cancer-associated pain and chemotherapy-induced neuropathy. Her work employs advanced microscopy to parse receptor organization changes that amplify pain signaling, with prospects for designing better pain management approaches for cancer patients.

The interplay between diet-derived xenobiotics and inflammation in cancer progression forms the basis of Dr. Esther J. Han’s work at Yale University. She studies how gut microbes and host cells chemically modify these plant-derived molecules, influencing cancer risk and inflammation, potentially guiding nutritional interventions to prevent or mitigate disease.

Dr. Qixiang He at Columbia University explores a novel bacterial antiviral defense that synthesizes DNA rather than cleaving it. By deciphering this system’s mechanisms, his research aims to develop innovative gene therapy delivery methods that circumvent immune reactions, potentially enhancing gene- and immunotherapies in cancer treatment.

Dr. King L. Hung at The Scripps Research Institute employs the regenerating flatworm as a model to study how chemical and mechanical signals integrate to maintain tissue integrity, a property lost in cancer. His live imaging approaches seek to untangle the multicellular circuitry that prevents unchecked proliferation and invasion.

Protein complexes essential for lung cancer progression are the subject of Dr. Jinho D. Jeong’s research at Massachusetts General Hospital. Using Molecular COUPLrs, a novel chemical biology technology, he aims to selectively disrupt complexes driving non-small cell lung cancers and brain metastases, potentially revealing new drug targets for these lethal diseases.

At the Broad Institute, Dr. Wenbin Mei studies the influence of inherited genetics on the development and aggressiveness of ERBB2-driven cancers, such as breast and lung cancers. His work aims to integrate germline and tumor genomic data to personalize risk prediction and therapy.

Dr. Rishi Kumar Mishra at the University of Michigan focuses on how the motor protein dynein localizes at microtubule plus-ends during cell migration, a process critical for cancer metastasis. Understanding this mechanism may identify vulnerabilities to inhibit cancer spread.

Dr. Christian G. Peace from Princeton University has developed novel in vivo technology for tracking nutrient utilization by cancer and immune cells within the tumor microenvironment. His work sheds light on the metabolic competition in tumors influencing immunotherapy efficacy.

Dr. Juntao Yu at Whitehead Institute investigates chromatin-based mechanisms guiding asymmetric cell division in stem cells, fundamental for tissue homeostasis and cancer prevention. Dissecting chromosome inheritance patterns may reveal how cancer cells bypass these controls.

Finally, Dr. Ming M. Zheng at the Broad Institute integrates large-scale genetics, single-molecule imaging, and AI to create dynamic maps of oncogene behavior in living cells, aiming to guide the creation of precise and long-lasting cancer therapies with minimal side effects.

Together, these fellows and awardees represent a vanguard of cancer research, tackling fundamental questions with cutting-edge tools across genetics, cell biology, immunology, and bioengineering. Their combined efforts underscore the Damon Runyon Cancer Research Foundation’s commitment to nurturing innovative science that holds promise for transformative advances in cancer prevention, diagnosis, and treatment worldwide.

Subject of Research: Cancer research focusing on fundamental mechanisms of tumorigenesis, metastasis, immunotherapy, epigenetics, and cellular communication.

Article Title: Damon Runyon Foundation Announces 2026 Fellows and Breakthrough Scientists Driving Cancer Research Innovation

News Publication Date: 2025-11

Web References: http://damonrunyon.org/

Keywords: Cancer research, postdoctoral fellows, tumorigenesis, immunotherapy, epigenetics, cellular metabolism, stem cells, DNA damage, translation regulation, tumor microenvironment, cancer genetics, synthetic biology

Traditional funding streams often necessitate extensive preliminary data, inadvertently sidelining bold projects that lack such evidence but hold transformative potential. The Damon Runyon-Rachleff Innovation Award fills this critical gap, championing innovative risk-taking by providing financial support and scientific validation from a rigorous selection process governed by an eminent panel of cancer research leaders. This framework ensures that only the most intellectually daring and methodologically sound proposals receive backing.

Dr. Timour Baslan from the University of Pennsylvania is pioneering therapeutic strategies centered on the enigmatic terrain of copy number alterations in cancer genomes, which are among the most prevalent mutational signatures across cancer types. His work delves into the vulnerabilities imposed by gene deletions in pancreatic cancer, utilizing an intersection of computational algorithms and chemical biology to identify and exploit these weaknesses. Given that recurrent deletions permeate the majority of tumor genomes, his findings carry significant promise for broad-spectrum therapeutic interventions.

At the University of California, San Francisco, Dr. Julia C. Carnevale’s research targets the enigmatic roles of dendritic cells within immunosuppressive tumor microenvironments. These antigen-presenting cells orchestrate the activation of cytotoxic T cells but are often rendered dysfunctional in solid tumors. By decoding and reprogramming dendritic cells to navigate hostile immune landscapes, Dr. Carnevale aims to invigorate adaptive immune responses, deploying engineered dendritic cells capable of coordinating multifaceted T cell networks, a potential breakthrough in overcoming immune evasion mechanisms inherent to many cancers.

Dr. Stephen T. Ferris of St. Louis University seeks to elucidate the interactions between natural killer T (NKT) cells, tumor cells, and lipid antigens—a frontier scarcely understood despite NKT cells’ pivotal bridging role between adaptive and innate immunity. His investigations focus on identifying tumor-derived lipid antigens that activate NKTs, unlocking mechanisms that could enable these cells to mount potent anti-tumor responses. This research could pave the way for novel immunotherapies leveraging the unique biology of lipid-reactive NKT cells across diverse malignancies.

A transformative approach to enhancing CAR T cell therapies is under pursuit by Dr. Evan W. Weber at The Children’s Hospital of Philadelphia. CAR T therapies have revolutionized hematologic cancer treatment yet face hurdles related to therapeutic durability and efficacy against solid tumors. Dr. Weber’s lab has developed a high-throughput platform to pinpoint the genetic and phenotypic characteristics that empower T cells to maintain serial killing capacity over time, paving the way for engineering CAR T cells capable of sustained tumor eradication with improved clinical outcomes.

At Dana-Farber Cancer Institute, Dr. Xin Zhou is revolutionizing how aberrant kinase signaling—a key driver across numerous malignancies and a frequent contributor to therapeutic resistance—is addressed. Traditional kinase inhibitors often falter due to the tumor’s adaptive mechanisms. By redirecting, or extracellularly reprogramming, kinase pathways to stimulate anti-tumor signaling rather than simply inhibiting them, Dr. Zhou’s work holds the promise of more durable and effective cancer therapeutics that circumvent resistance pathways.

Among the recipients earning Stage 2 funding continuation is Dr. Daniel J. Puleston from Mount Sinai, who is innovating ex situ maintenance techniques that keep tumor-bearing human organs viable outside the body. This groundbreaking platform facilitates real-time study of tumor biology and therapeutic responses in an intact human microenvironment, offering unprecedented mechanistic insights into hepatocellular carcinoma’s metabolic vulnerabilities and its interaction with immunotherapy agents, potentially streamlining drug development pipelines.

Dr. Humsa S. Venkatesh at Brigham and Women’s Hospital is unraveling the intricate bioelectric signaling circuits that orchestrate brain cancer progression. Recognizing that neuronal activity modulates cancer heterogeneity, Dr. Venkatesh applies systems neuroscience to decode interactions between malignant cells and the nervous system. This holistic approach seeks to identify therapeutic targets aimed at normalizing aberrant bioelectric neural circuits that fuel tumor growth, thereby offering new avenues for intervention in treatment-resistant brain cancers.

At the University of California, Berkeley, Dr. Ziyang Zhang is engineering a chemically tunable immunotherapy platform to enhance the safety and control of bispecific T cell engager antibodies (BiTEs). While BiTEs have demonstrated remarkable efficacy, their clinical utility is often constrained by severe toxicities. Dr. Zhang’s ‘chemical switch’ concept promises a revolutionary leap by enabling rapid modulation of BiTE activity, potentially allowing safe administration at efficacious doses that can penetrate solid tumors and mitigate side effects.

The Damon Runyon Cancer Research Foundation’s extensive legacy of accelerating early-career scientific breakthroughs is epitomized by this cohort of innovators. With a portfolio including 13 Nobel laureates and an investment exceeding $491 million in nearly 4,100 scientists since 1946, the Foundation remains at the vanguard of cultivating the audacity and creativity essential to conquering cancer. These new projects underscore the power of risk-taking science—embracing complexity and uncertainty to unlock transformative insights capable of reshaping oncologic care globally.

Beyond funding, the Damon Runyon-Rachleff Innovation Award nurtures a vibrant intellectual ecosystem where rigorous peer evaluation and interdisciplinary collaboration thrive. This environment empowers researchers to chart uncharted territories of cancer biology, from genomic aberrations and kinase signaling to immune cell engineering and bioelectric circuit manipulation. Each investigator’s program is a testament to the belief that the most profound advances emerge when visionary science meets robust support.

As these outstanding scientists embark on their groundbreaking work, the anticipation mounts for discoveries that promise to deepen our understanding of cancer’s multifaceted biology and yield novel therapeutic modalities. Through sustained innovation and relentless pursuit of high-impact ideas, the Damon Runyon-Rachleff Innovation Award continues to propel the frontier of cancer research, offering renewed hope for patients and a beacon for the scientific community worldwide.

Subject of Research: Innovative cancer biology and immunotherapy targeting genomic alterations, immune cell reprogramming, kinase signaling, tumor microenvironments, and novel therapeutic platforms.

Article Title: Groundbreaking Innovations Poised to Reshape Cancer Research: Meet the 2026 Damon Runyon-Rachleff Innovators

News Publication Date: 2026

Web References: http://damonrunyon.org/

Keywords: Cancer research, Translational research, Cancer treatments, Cancer immunotherapy, Tumor microenvironments, Brain cancer, Kinase signaling, Oncogenes, Carcinogenesis